NCT05770895 - Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 3, 2023

Primary Completion Date

January 15, 2025

Study Completion Date

January 15, 2025

Conditions

Chronic Hepatitis B

Interventions

BIOLOGICAL

GS-2829

Administered intramuscularly

BIOLOGICAL

GS-6779

Administered intramuscularly

BIOLOGICAL

Placebo for GS-2829

Administered intramuscularly

BIOLOGICAL

Placebo for GS-6779

Administered intramuscularly

Trial Locations (9)

St. Martin De Porres Hospital, Chiayi City

Kaohsiung Medical University Hospital, Kaohsiung City

Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

New Zealand Clinical Research (NZCR), Auckland

National Cheng Kung University Hospital, Tainan City

Chang Gung Medical Foundation Linkou Chang Gung Memorial Hospital, Taoyuan

Chia-Yi Christian Hospital, Chiayi City

E-DA Hospital, Kaohsiung City

National Taiwan University Hospital, Taipei